AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19214375 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day etidronate (Group E)
Number of subjects: 199
Study 19214375 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day risedronate (Group R)
Number of subjects: 199
Study 19214375 — intervention group
Group type: COMPARATOR
Intervention: No bisphosphonate (Group P)
Number of subjects: 199
Study 17408422 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (cycle 1)
Number of subjects: 12
Study 17408422 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (cycle 2)
Number of subjects: 12
Study 17408422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (cycle 3)
Number of subjects: 12
Study 14731170 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART treatment
Number of subjects: 120
Study 14731170 — intervention group
Group type: COMPARATOR
Intervention: Non-HAART treatment (antimicrobial therapy)
Number of subjects: 120
Study 11464146 — intervention group
Group type: EXPERIMENTAL
Intervention: Double combination antiretroviral therapy (zidovudine and lamivudine)
Number of subjects: 0
Study 11464146 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination antiretroviral therapy (zidovudine, lamivudine, and ritonavir)
Number of subjects: 0
Study 11464146 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antiretroviral therapy among nonresponders
Number of subjects: 0
Study 9010907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric office-based intervention providing advice and materials at well-care visits during the first 6 months postpartum
Number of subjects: 2901
Study 9010907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2901
Study 9010907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric office-based intervention
Number of subjects: 2901
Study 7654481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (3.2 to 12.2 micrograms kg‐1 i.v. bolus)
Number of subjects: 0
Study 7654481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 0
Study 7654481 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline
Number of subjects: 0
Study 2808786 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% ammonium lactate lotion
Number of subjects: 0
Study 2808786 — intervention group
Group type: COMPARATOR
Intervention: 5% lactic acid lotion
Number of subjects: 0
Study 1091434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide Ratiopharm (1,000 mg)
Number of subjects: 16
Study 1091434 — intervention group
Group type: COMPARATOR
Intervention: Rastinon 1,0 Hoechst
Number of subjects: 16
Study 31908129 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 1561
Study 31870306 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Occupational Therapy in Dementia-UK intervention (COTiD-UK)
Number of subjects: 31
Study 28419188 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive book reading
Number of subjects: 27
Study 25765720 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (4mg)
Number of subjects: 11
Study 25765720 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (10mg)
Number of subjects: 11
Study 25765720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23339054 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption >12 ounces of coffee/day
Number of subjects: 0
Study 23339054 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption between 4 and 12 ounces/day
Number of subjects: 0
Study 23339054 — intervention group
Group type: COMPARATOR
Intervention: Caffeine consumption <4 ounces/day
Number of subjects: 0
Study 21147825 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/day with option for dose escalation)
Number of subjects: 1070
Study 21147825 — intervention group
Group type: COMPARATOR
Intervention: Comparator (liposomal amphotericin B or caspofungin)
Number of subjects: 1070
Study 21147825 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/day)
Number of subjects: 1070
Study 19446150 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (dispersible tablet) of amlodipine besylate (10 mg)
Number of subjects: 20
Study 19446150 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (established tablet) of amlodipine besylate (10 mg)
Number of subjects: 20
Study 19446150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus (moist group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexit (moist group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: RoekoSeal (moist group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubli‐Seal (moist group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Endo (moist group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus (dry group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexit (dry group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: RoekoSeal (dry group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubli‐Seal (dry group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Endo (dry group)
Number of subjects: 120
Study 17185125 — intervention group
Group type: COMPARATOR
Intervention: Control group (AH Plus, lateral condensation)
Number of subjects: 120
Study 14742377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (18 mg, ED(50) 95% CI: 16-18 mg)
Number of subjects: 60
Study 14742377 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg, ED(50) 95% CI: 4-6 mg)
Number of subjects: 60
Study 14742377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nefopam (12 mg, 3:1 ratio) and Morphine (4 mg, ED(50) 95% CI: 3.5-4.5 mg)
Number of subjects: 60
Study 14742377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam and Morphine combination
Number of subjects: 60
Study 14742377 — intervention group
Group type: COMPARATOR
Intervention: Nefopam and Morphine
Number of subjects: 60
Study 11316269 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h mild hypoxia (inspired PO2 127 mmHg)
Number of subjects: 12
Study 11316269 — intervention group
Group type: COMPARATOR
Intervention: Air-breathing (control)
Number of subjects: 12
Study 9040200 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., metronidazole 400 mg b.i.d.)
Number of subjects: 231
Study 9040200 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM (omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., metronidazole 400 mg b.i.d.)
Number of subjects: 231
Study 9040200 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM (bismuth subcitrate 240 mg b.i.d., clarithromycin 250 mg b.i.d., metronidazole 400 mg b.i.d.)
Number of subjects: 231
Study 7943672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 72
Study 7943672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7943672 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 72
Study 3317347 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived vaccine (10, 20, or 40 micrograms)
Number of subjects: 339
Study 3317347 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived vaccine (5 micrograms, Institut Pasteur Production)
Number of subjects: 339
Study 3317347 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived vaccine (20 micrograms, Merck Sharp & Dohme)
Number of subjects: 339
Study 30097463 — intervention group
Group type: EXPERIMENTAL
Intervention: SC411 at 20 mg DHA/kg per day
Number of subjects: 67
Study 30097463 — intervention group
Group type: EXPERIMENTAL
Intervention: SC411 at 36 mg DHA/kg per day
Number of subjects: 67
Study 30097463 — intervention group
Group type: EXPERIMENTAL
Intervention: SC411 at 60 mg DHA/kg per day
Number of subjects: 67
Study 30097463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30097463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled active groups (SC411 at 20, 36, and 60 mg DHA/kg per day)
Number of subjects: 67
Study 30097463 — intervention group
Group type: EXPERIMENTAL
Intervention: SC411 (all doses)
Number of subjects: 67
Study 23460704 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pemoline
Number of subjects: 0
Study 23460704 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting methylphenidate (MPH)
Number of subjects: 0
Study 23460704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 0
Study 26094763 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Number of subjects: 200
Study 26094763 — intervention group
Group type: COMPARATOR
Intervention: Nurse titrated analgesia (treatment as usual)
Number of subjects: 200
Study 22956399 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 14
Study 22956399 — intervention group
Group type: COMPARATOR
Intervention: 3D game
Number of subjects: 14
Study 21593292 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 23
Study 21593292 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 23
Study 19840018 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of bleomycin, etoposide and cisplatin (3BEP)
Number of subjects: 0
Study 19840018 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of etoposide and cisplatin (4EP)
Number of subjects: 0
Study 19840018 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP regimen adjustments
Number of subjects: 0
Study 19840018 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients with germ-cell cancer
Number of subjects: 0
Study 16818416 — intervention group
Group type: EXPERIMENTAL
Intervention: Perftoran (PFC) group, n = 15
Number of subjects: 30
Study 16818416 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 15
Number of subjects: 30
Study 14509556 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP therapy
Number of subjects: 9
Study 10849389 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection into the ipsilateral medial rectus muscle
Number of subjects: 84
Study 10849389 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 84
Study 10849389 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection (unilateral)
Number of subjects: 84
Study 10849389 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (unilateral)
Number of subjects: 84
Study 10849389 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection (bilateral)
Number of subjects: 84
Study 10849389 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (bilateral)
Number of subjects: 84
Study 8886735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of morphine
Number of subjects: 40
Study 8886735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of lidocaine
Number of subjects: 40
Study 8886735 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study 8886735 — intervention group
Group type: EXPERIMENTAL
Intervention: All tests (including saline)
Number of subjects: 40
Study 1596121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (synthetic prostaglandin E1), 20 ng.kg‐1.min‐1, intravenous infusion during operation
Number of subjects: 24
Study 1596121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alprostadil)
Number of subjects: 24
Study 1596121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (synthetic prostaglandin E1)
Number of subjects: 24
Study 6721404 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon administration
Number of subjects: 79
Study 6721404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucagon)
Number of subjects: 79
Study 31764466 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (12 weeks, 10.5 MJ·wk)
Number of subjects: 46
Study 31764466 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control
Number of subjects: 46
Study 30592477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherent participants (6954 individuals)
Number of subjects: 77443
Study 30592477 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially adherent participants (2548 individuals)
Number of subjects: 77443
Study 30592477 — intervention group
Group type: COMPARATOR
Intervention: Fully adherent participants (55065 individuals)
Number of subjects: 77443
Study 28238161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure™ (Group L)
Number of subjects: 60
Study 28238161 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic (Group H)
Number of subjects: 60
Study 28238161 — intervention group
Group type: COMPARATOR
Intervention: Conventional (Group C)
Number of subjects: 60
Study 28238161 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 28238161 — intervention group
Group type: EXPERIMENTAL
Intervention: EBDs (especially Group L)
Number of subjects: 60
Study 26874508 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM)
Number of subjects: 176
Study 26874508 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB)
Number of subjects: 176
Study 26874508 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 176
Study 24630939 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-addiction model of obesity
Number of subjects: 625
Study 24630939 — intervention group
Group type: COMPARATOR
Intervention: Non-addiction model of obesity
Number of subjects: 625
Study 23135301 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite Heart Health Improvement Project (WHHIP)
Number of subjects: 39
Study 23135301 — intervention group
Group type: COMPARATOR
Intervention: Control site (education only)
Number of subjects: 39
Study 18631332 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine HCI 0.1%
Number of subjects: 100
Study 18631332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025%
Number of subjects: 100
Study 18631332 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine HCI 0.05%
Number of subjects: 100
Study 18631332 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine 0.05%
Number of subjects: 100
Study 18631332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone acetate 0.1%
Number of subjects: 100
Study 18631332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18631332 — intervention group
Group type: EXPERIMENTAL
Intervention: All antiallergic agents
Number of subjects: 100
Study 16971674 — intervention group
Group type: EXPERIMENTAL
Intervention: online‐tailored physical activity advice + stage‐based reinforcement e‐mails
Number of subjects: 526
Study 16971674 — intervention group
Group type: EXPERIMENTAL
Intervention: online‐tailored physical activity advice only
Number of subjects: 526
Study 16971674 — intervention group
Group type: COMPARATOR
Intervention: online non‐tailored standard physical activity advice
Number of subjects: 526
Study 15341550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping On program
Number of subjects: 310
Study 15341550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping On program (subgroup analysis for men)
Number of subjects: 310
Study 11134190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg daily for 3 years
Number of subjects: 282
Study 11134190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 282
Study 9589247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 18
Study 9589247 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 18
Study 8033763 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 0
Study 8033763 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 2647105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate potassium treatment
Number of subjects: 221
Study 2647105 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 221
Study 786672 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of acebutolol
Number of subjects: 6
Study 786672 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of acebutolol
Number of subjects: 6
Study 786672 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of acebutolol (placebo)
Number of subjects: 6
Study 31601229 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mix (Lactobacillus acidophillus + Bifidobacterium lactis + Lactobacillus rhamnosus + Lactobacillus paracasei, 1 x 10^9 CFU for each, 2 sachets/day for 24 weeks)
Number of subjects: 0
Study 31601229 — intervention group
Group type: COMPARATOR
Intervention: Placebo identical in all characteristics and packaging, 2 sachets/day for 24 weeks
Number of subjects: 0
Study 28283902 — intervention group
Group type: COMPARATOR
Intervention: IV only
Number of subjects: 376
Study 28283902 — intervention group
Group type: EXPERIMENTAL
Intervention: IA only
Number of subjects: 376
Study 28283902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined (IV + IA injection of 1 g)
Number of subjects: 376
Study 28283902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose combined (IV + IA injection of 2 g)
Number of subjects: 376
Study 25580725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with rifapentine and isoniazid (12 once-weekly doses for 3 months)
Number of subjects: 905
Study 25580725 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid only (270 daily doses for 9 months)
Number of subjects: 905
Study 25580725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with rifapentine and isoniazid
Number of subjects: 905
Study 25580725 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid only
Number of subjects: 905
Study 25580725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 905
Study 22681407 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release hydromorphone
Number of subjects: 459
Study 22681407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 22024000 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Bup/Nal) therapy for 12 weeks
Number of subjects: 152
Study 22024000 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/naloxone detoxification for up to 2 weeks with weekly individual and group drug counseling
Number of subjects: 152
Study 22024000 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment opioid abstinence (weeks 1 and 2)
Number of subjects: 152
Study 22024000 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional nonstudy treatments during the study
Number of subjects: 152
Study 19166684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (low or high doses)
Number of subjects: 1273
Study 19166684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1273
Study 19166684 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (low-dose)
Number of subjects: 1273
Study 16601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication (methylphenidate)
Number of subjects: 79
Study 12845508 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran plus ASA
Number of subjects: 12
Study 12845508 — intervention group
Group type: COMPARATOR
Intervention: Melagatran
Number of subjects: 12
Study 11126152 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 800 mg intravenous fesin (ferric saccharate)
Number of subjects: 18
Study 11126152 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg intravenous fesin once weekly for 2 successive weeks
Number of subjects: 18
Study 11126152 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of intravenous fesin for 7 successive hemodialysis sessions
Number of subjects: 18
Study 9088054 — intervention group
Group type: EXPERIMENTAL
Intervention: Essays about negative experiences
Number of subjects: 0
Study 9088054 — intervention group
Group type: COMPARATOR
Intervention: Essays about trivial events
Number of subjects: 0
Study 8414819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (2 mg/kg)
Number of subjects: 75
Study 8414819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3332128 — intervention group
Group type: EXPERIMENTAL
Intervention: One-log T-lymphocyte depletion (average T-lymphocyte content of 50 X 10(5)/kg body weight, n = 9 patients)
Number of subjects: 18
Study 3332128 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-log T-lymphocyte depletion (average T-lymphocyte content of 15 X 10(4)/kg body weight, n = 9 patients)
Number of subjects: 18
Study 30872387 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-generated alert
Number of subjects: 1123
Study 30872387 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1123
Study 29091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched treatment (alternating treatment with biosimilar and reference filgrastim)
Number of subjects: 218
Study 29091995 — intervention group
Group type: COMPARATOR
Intervention: Reference filgrastim (Neupogen®)
Number of subjects: 218
Study 26871448 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum breastfeeding clinic
Number of subjects: 472
Study 26871448 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 472
Study 24218500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 199
Study 24218500 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 199
Study 22512425 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance sheet program for physical activity
Number of subjects: 21
Study 22512425 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance sheet program for fruit and vegetable consumption
Number of subjects: 21